<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The optimal pretransplant regimen for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in patients ≥ 55 years of age remains to be determined </plain></SENT>
<SENT sid="1" pm="."><plain>The myeloablative reduced-toxicity 4-day regimen i.v. <z:chebi fb="0" ids="28901">busulfan</z:chebi> (Bu) (130 mg/m(2)) and i.v. fludarabine (Flu) (40 mg/m(2)) is associated with low morbidity and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed 79 patients ≥ 55 years of age (median, 58 years) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 63) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n = 16) treated with i.v </plain></SENT>
<SENT sid="3" pm="."><plain>Bu-Flu conditioning regimens between 2001 and 2009 (median follow-up, 24 months) </plain></SENT>
<SENT sid="4" pm="."><plain>The patients who received this regimen had a good performance status </plain></SENT>
<SENT sid="5" pm="."><plain>The 2-year overall survival (OS) rates for patients in first complete remission (CR1), second CR (CR2), or refractory disease and for <z:hpo ids='HP_0000001'>all</z:hpo> patients at time of transplantation were 71%, 44%, 32%, and 46%, respectively; 2-year event-free survival (EFS) rates for patients in CR1, CR2, or refractory disease at time of transplantation and for <z:hpo ids='HP_0000001'>all</z:hpo> patients were 68%, 42%, 30%, and 44%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>One-year transplant-related mortality (TRM) rates for patients who were in CR or who had active disease at the time of transplantation were 19% and 20%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> graft-versus-host (aGVHD) disease was diagnosed in 40% of the patients </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v </plain></SENT>
<SENT sid="9" pm="."><plain>Bu-Flu preceding transplantation in patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
</text></document>